Values as of: 2025-01-08
COMMON STOCK | Biotechnology |
Last Closing
USD 23.43Change
-0.51 (-2.13)%Market Cap
USD 1.70BVolume
0.44MAnalyst Target
USD 45.64Verdict
Verdict
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Company Website : https://www.xencor.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+3.79 (+0.93%) |
USD 104.84B |
| REGN | Regeneron Pharmaceuticals Inc |
+3.29 (+0.45%) |
USD 78.92B |
| ARGX | argenx NV ADR |
+0.64 (+0.10%) |
USD 36.54B |
| ALNY | Alnylam Pharmaceuticals Inc |
+4.60 (+1.95%) |
USD 30.22B |
| MRNA | Moderna Inc |
-4.36 (-9.17%) |
USD 18.29B |
| UTHR | United Therapeutics Corporatio.. |
+4.28 (+1.18%) |
USD 15.91B |
| RPRX | Royalty Pharma Plc |
+0.16 (+0.61%) |
USD 15.05B |
| SMMT | Summit Therapeutics PLC |
+0.66 (+3.63%) |
USD 13.43B |
| INCY | Incyte Corporation |
-0.06 (-0.08%) |
USD 13.41B |
| BMRN | Biomarin Pharmaceutical Inc |
+0.48 (+0.71%) |
USD 12.74B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| CNCR | Loncar Cancer Immunothera.. | 1.88 % | 0.79 % |
-0.39 (-2.99%) |
USD 0.01B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 1.96% | 51% | F | 67% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.96% | 51% | F | 67% | D+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 14.40% | 73% | C | 69% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 14.40% | 73% | C | 66% | D+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | -33.85% | 67% | D+ | 33% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -33.85% | 66% | D+ | 31% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -8.51% | 35% | F | 22% | F | ||
| Dividend Return | -8.51% | 35% | F | 22% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 25.01% | 93% | A | 70% | C- | ||
| Risk Adjusted Return | -34.05% | 27% | F | 18% | F | ||
| Market Capitalization | 1.70B | 86% | B+ | 77% | C+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total free cash flow in the most recent four quarters.
